Association of tamoxifen resistance and lipid reprogramming in breast cancer

BACKGROUND: Tamoxifen treatment of estrogen receptor (ER)-positive breast cancer reduces mortality by 31%. However, over half of advanced ER-positive breast cancers are intrinsically resistant to tamoxifen and about 40% will acquire the resistance during the treatment. METHODS: In order to explore m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hultsch, Susanne, Kankainen, Matti, Paavolainen, Lassi, Kovanen, Ruusu-Maaria, Ikonen, Elina, Kangaspeska, Sara, Pietiäinen, Vilja, Kallioniemi, Olli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109356/
https://www.ncbi.nlm.nih.gov/pubmed/30143015
http://dx.doi.org/10.1186/s12885-018-4757-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109356/
https://www.ncbi.nlm.nih.gov/pubmed/30143015
http://dx.doi.org/10.1186/s12885-018-4757-z

Ejemplares similares